The device is claimed to provide comprehensive protection to brain and body from ischemic events such as strokes. Credit: earth phakphum/ Shutterstock.

Medical technology company Emboline has filed a patent infringement lawsuit against Italy-based AorticLab, alleging that the latter infringed its intellectual property.

The complaint was lodged on 28 October with the Unified Patent Court’s local division in Munich, Germany.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The lawsuit is linked to Emboline’s embolic medical device, which is intended to offer protection from ischemic events.

Dubbed the Emboliner Embolic Protection Catheter, the device is claimed to provide comprehensive protection to the brain and body from ischemic events such as strokes, resulting from embolic debris release into the bloodstream at the time of transcatheter heart procedures.

Emboline president and CEO Scott Russell said: “Emboline pioneered TAVR embolic protection starting with the introduction of transcatheter aortic valve replacement in 2002. Emboline has since built a significant portfolio of intellectual property surrounding embolic protection.

“Strokes remain a real and devastating consequence of TAVR, and the need for safe, effective and easy-to-use embolic protection had resulted in several companies pursuing this market, with some designs emulating key protected features of the Emboliner device. Emboline wants to make clear that we will vigorously defend our intellectual property.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Emboline has secured additional patents for embolic protection technologies that could be applied across various interventional procedures.

Currently, the company is carrying out the Protect the Head to Head IDE trial of the Emboliner, treating the first subject, in May 2023.

The patient was treated at New York-Presbyterian Hospital/Columbia University Medical Center in the US.

This study aims to validate the safety of the device against a control device to reduce stroke risk from transcatheter aortic valve replacement (TAVR).